Business
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data will be presented in late-breaking poster presentation at the European Association for the Stud
About this update from Metavia Inc.
[{"type":"text","content":"DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment ","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Liver Fat Content","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"Improvement in Systemic Inflammatory and Fibrosis Biomarkers Supports Beneficial Effects on Liver Health","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data will be presented in late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place May 7-10, 2025, in Amsterdam, the Netherlands.","length":647,"tagName":"p"},{"type":"image","alt":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","displaySize":"","headline":null,"caption":"MetaVia Logo (PRNewsfoto/MetaVia Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":77,"url":"https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oKeVzvlzHhGood7_jpA63w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","width":400,"height":77}},"href":"https://mma.prnewswire.com/media/2568660/MetaVia_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"A total of 109 subjects with presumed MASH and qualifying baseline alanine transaminase (ALT) and imaging analysis were randomized to receive DA-1241 50 mg, DA-1241 100 mg alone, DA-1241 100 mg with a dipeptidyl peptidase 4 inhibitor (DPP4i), or placebo (PBO) in a 1:2:2:2 ratio, once daily for 16 weeks. The primary efficacy endpoint was the change from baseline in ALT after 16 weeks of treatment.","length":399,"tagName":"p"},{"type":"text","content":""The full data from our Phase 2...